Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women

M. Ushioda, Kazuya Makita, K. Takamatsu, F. Horiguchi, Daisuke Aoki

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Aim: To assess lipoprotein(a) [Lp(a)] dynamics before and after menopause and to examine long-term changes during hormone replacement therapy (HRT) in middle-aged and older Japanese women. Methods: (1) Serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and Lp(a) concentrations of 526 patients were compared. The patients were divided into 3 groups on the basis of menopausal status (premenopause, perimenopause, postmenopause). (2) Serum markers of lipid metabolism were measured at baseline and at 6-month intervals in 161 postmenopausal women who continuously received HRT with conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) for 4 years. (3) Changes in serum concentrations of markers were compared among 120 women with hypercholesterolemia who were randomly assigned to receive HRT (CEE plus MPA, or transdermal estradiol plus MPA) or pravastatin. Results: (1) Lp(a) concentrations were significantly higher in the postmenopausal women than in the premenopausal or perimenopausal women. (2) The mean Lp(a) concentration after 6 months of HRT decreased by about 19%, and similar levels were maintained for 4 years (3). The mean Lp(a) concentration after 6 months of HRT decreased by 19.9% in the CEE plus MPA group, but did not change significantly in the transdermal estradiol plus MPA group or the pravastatin group. Conclusion: Our results suggest that HRT with CEE plus MPA is useful for the management of elevated serum Lp(a) concentrations in middle-aged and older women. However, follow-up studies are needed to determine whether this finding is related to the future prevention of coronary heart disease events.

Original languageEnglish
Pages (from-to)581-586
Number of pages6
JournalHormone and Metabolic Research
Volume38
Issue number9
DOIs
Publication statusPublished - 2006 Sep

Fingerprint

Medroxyprogesterone Acetate
Lipoprotein(a)
Hormone Replacement Therapy
Menopause
Conjugated (USP) Estrogens
Hormones
Serum
Pravastatin
Estradiol
Biomarkers
Perimenopause
Postmenopause
Cholesterol
Hypercholesterolemia
Lipid Metabolism
LDL Cholesterol
HDL Cholesterol
Coronary Disease

Keywords

  • Estrogen
  • Hormone replacement therapy
  • Lipoprotein(a)
  • Menopause
  • Pravastatin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women. / Ushioda, M.; Makita, Kazuya; Takamatsu, K.; Horiguchi, F.; Aoki, Daisuke.

In: Hormone and Metabolic Research, Vol. 38, No. 9, 09.2006, p. 581-586.

Research output: Contribution to journalArticle

@article{e2008be9995341878b9a56a59dbebcc5,
title = "Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women",
abstract = "Aim: To assess lipoprotein(a) [Lp(a)] dynamics before and after menopause and to examine long-term changes during hormone replacement therapy (HRT) in middle-aged and older Japanese women. Methods: (1) Serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and Lp(a) concentrations of 526 patients were compared. The patients were divided into 3 groups on the basis of menopausal status (premenopause, perimenopause, postmenopause). (2) Serum markers of lipid metabolism were measured at baseline and at 6-month intervals in 161 postmenopausal women who continuously received HRT with conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) for 4 years. (3) Changes in serum concentrations of markers were compared among 120 women with hypercholesterolemia who were randomly assigned to receive HRT (CEE plus MPA, or transdermal estradiol plus MPA) or pravastatin. Results: (1) Lp(a) concentrations were significantly higher in the postmenopausal women than in the premenopausal or perimenopausal women. (2) The mean Lp(a) concentration after 6 months of HRT decreased by about 19{\%}, and similar levels were maintained for 4 years (3). The mean Lp(a) concentration after 6 months of HRT decreased by 19.9{\%} in the CEE plus MPA group, but did not change significantly in the transdermal estradiol plus MPA group or the pravastatin group. Conclusion: Our results suggest that HRT with CEE plus MPA is useful for the management of elevated serum Lp(a) concentrations in middle-aged and older women. However, follow-up studies are needed to determine whether this finding is related to the future prevention of coronary heart disease events.",
keywords = "Estrogen, Hormone replacement therapy, Lipoprotein(a), Menopause, Pravastatin",
author = "M. Ushioda and Kazuya Makita and K. Takamatsu and F. Horiguchi and Daisuke Aoki",
year = "2006",
month = "9",
doi = "10.1055/s-2006-950504",
language = "English",
volume = "38",
pages = "581--586",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "9",

}

TY - JOUR

T1 - Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women

AU - Ushioda, M.

AU - Makita, Kazuya

AU - Takamatsu, K.

AU - Horiguchi, F.

AU - Aoki, Daisuke

PY - 2006/9

Y1 - 2006/9

N2 - Aim: To assess lipoprotein(a) [Lp(a)] dynamics before and after menopause and to examine long-term changes during hormone replacement therapy (HRT) in middle-aged and older Japanese women. Methods: (1) Serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and Lp(a) concentrations of 526 patients were compared. The patients were divided into 3 groups on the basis of menopausal status (premenopause, perimenopause, postmenopause). (2) Serum markers of lipid metabolism were measured at baseline and at 6-month intervals in 161 postmenopausal women who continuously received HRT with conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) for 4 years. (3) Changes in serum concentrations of markers were compared among 120 women with hypercholesterolemia who were randomly assigned to receive HRT (CEE plus MPA, or transdermal estradiol plus MPA) or pravastatin. Results: (1) Lp(a) concentrations were significantly higher in the postmenopausal women than in the premenopausal or perimenopausal women. (2) The mean Lp(a) concentration after 6 months of HRT decreased by about 19%, and similar levels were maintained for 4 years (3). The mean Lp(a) concentration after 6 months of HRT decreased by 19.9% in the CEE plus MPA group, but did not change significantly in the transdermal estradiol plus MPA group or the pravastatin group. Conclusion: Our results suggest that HRT with CEE plus MPA is useful for the management of elevated serum Lp(a) concentrations in middle-aged and older women. However, follow-up studies are needed to determine whether this finding is related to the future prevention of coronary heart disease events.

AB - Aim: To assess lipoprotein(a) [Lp(a)] dynamics before and after menopause and to examine long-term changes during hormone replacement therapy (HRT) in middle-aged and older Japanese women. Methods: (1) Serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and Lp(a) concentrations of 526 patients were compared. The patients were divided into 3 groups on the basis of menopausal status (premenopause, perimenopause, postmenopause). (2) Serum markers of lipid metabolism were measured at baseline and at 6-month intervals in 161 postmenopausal women who continuously received HRT with conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) for 4 years. (3) Changes in serum concentrations of markers were compared among 120 women with hypercholesterolemia who were randomly assigned to receive HRT (CEE plus MPA, or transdermal estradiol plus MPA) or pravastatin. Results: (1) Lp(a) concentrations were significantly higher in the postmenopausal women than in the premenopausal or perimenopausal women. (2) The mean Lp(a) concentration after 6 months of HRT decreased by about 19%, and similar levels were maintained for 4 years (3). The mean Lp(a) concentration after 6 months of HRT decreased by 19.9% in the CEE plus MPA group, but did not change significantly in the transdermal estradiol plus MPA group or the pravastatin group. Conclusion: Our results suggest that HRT with CEE plus MPA is useful for the management of elevated serum Lp(a) concentrations in middle-aged and older women. However, follow-up studies are needed to determine whether this finding is related to the future prevention of coronary heart disease events.

KW - Estrogen

KW - Hormone replacement therapy

KW - Lipoprotein(a)

KW - Menopause

KW - Pravastatin

UR - http://www.scopus.com/inward/record.url?scp=33750029958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750029958&partnerID=8YFLogxK

U2 - 10.1055/s-2006-950504

DO - 10.1055/s-2006-950504

M3 - Article

VL - 38

SP - 581

EP - 586

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 9

ER -